Clinical trials: Stage I Bladder Cancer AJCC v8
Bladder Cancer
Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer
RATIONALE: Learning about the long-term effects of dietary, lifestyle, and environmental factors on the risk of cancer progression and recurrence may help the study of bladder cancer in the future.
- Trial name
- NCT00553566
- Testing
- medical chart review, questionnaire administration, study of socioeconomic and demographic variables
- Where
- United Kingdom
- Volunteers
- 1,600 people
- Sponsor
- University of Birmingham
Bladder Cancer
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00004122
- Testing
- BCG vaccine, recombinant interferon alfa
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of…
- Conditions
- Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- GAIN-BCG (NCT07000084)
- Testing
- BCG Solution, Biopsy of Bladder, Cystoscopy
- Where
- 60 sites in United States
- Volunteers
- 330 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Bladder Cancer
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005047
- Testing
- cisplatin, doxorubicin hydrochloride, methotrexate
- Where
- 74 sites in United States, Canada
- Volunteers
- 521 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer
AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from…
- Trial name
- NCT00003759
- Testing
- BCG vaccine, valrubicin, conventional surgery
- Where
- United States
- Sponsor
- Anthra Pharmaceuticals
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
This phase I trial tests the safety and side effects of a PD-L1/IDO peptide vaccine (IO102-IO103) in combination with pembrolizumab in treating patients with non-muscle invasive bladder cancer.
- Conditions
- High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- NCT05843448
- Testing
- PD-L1/IDO Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Davis
Bladder Cancer
Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer
RATIONALE: New diagnostic procedures such as microsatellite analysis of sediment in the urine may improve the ability to detect bladder cancer without invasive procedures.
- Trial name
- NCT00095589
- Testing
- loss of heterozygosity analysis, microarray analysis, microsatellite instability analysis
- Where
- 13 sites in United States, Canada
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bladder Papillary Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma
Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder Cancer
This research trial studies two types of tests, an ultrasound test and a biomarker test, to see how well they predict how aggressive (invasive) bladder cancer is in samples from patients with bladder cancer.
- Conditions
- Bladder Papillary Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Cancer With Carcinoma In Situ
- Trial name
- NCT02494635
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Southern California
Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer
This phase II trial studies the safety and feasibility of utilizing acupuncture in patients with high-risk bladder cancer that has not spread to the surrounding muscle (non-muscle invasive) undergoing treatment with Intravesical…
- Conditions
- Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
- Trial name
- NCT04496219
- Testing
- Acupuncture Therapy, BCG Solution, Best Practice
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fred Hutchinson Cancer Center
Bladder Cancer, Cervical Cancer
Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
RATIONALE: Radiation therapy can cause long-term adverse effects. Hyperbaric oxygen therapy may be effective in lessening gastrointestinal symptoms caused by radiation therapy given for pelvic cancer.
- Conditions
- Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer
- Trial name
- NCT01087268
- Testing
- questionnaire administration, gastrointestinal complications management/prevention, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Bladder Cancer
Biological Therapy in Treating Patients With Bladder Cancer
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known which type of BCG is more effective for bladder cancer.
- Trial name
- NCT00003779
- Testing
- Connaught, Tice
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Swiss Cancer Institute
Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
This phase II trial studies the side effects of pembrolizumab and to see how well it works in treating patients with bladder cancer who are undergoing surgery to remove the bladder.
- Conditions
- Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT03319745
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
This phase I trial tests the safety, tolerability and effectiveness of PLZ4-coated paclitacel-loaded micelles (PPM) in treating patients with non-muscle invasive bladder cancer that has come back after a period of improvement…
- Conditions
- Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- NCT06173349
- Testing
- PLZ4-coated paclitaxel loaded micelles (PPM)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, Davis
Bladder Cancer
Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer and may have fewer side effects and improve recovery.
- Trial name
- NCT00003725
- Testing
- valrubicin, conventional surgery
- Where
- 53 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Anthra Pharmaceuticals
Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
This study evaluates the effect of bladder cancer treatment on quality of life.
- Conditions
- Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8
- Trial name
- NCT06350734
- Testing
- Non-Interventional Study
- Where
- 3 sites in United States
- Volunteers
- 204 people
- Sponsor
- Mayo Clinic
Bladder Cancer
Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00004154
- Testing
- Fenretinide
- Where
- 3 sites in United States
- Volunteers
- 111 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer
Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Drugs used in chemotherapy, such as mitomycin C and epirubicin hydrochloride, work in different ways to stop the…
- Trial name
- NCT01094964
- Testing
- BCG solution, recombinant interferon alfa, epirubicin hydrochloride
- Where
- 9 sites in United Kingdom
- Volunteers
- 242 people
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
Bladder Cancer, Kidney Cancer
Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants
RATIONALE: Studying samples of blood and urine from patients with cancer and from healthy participants in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Bladder Cancer, Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00900276
- Testing
- immunologic technique, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Localized Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8
Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial
This clinical trial compares how well a home-based personalized physical activity program (PAP) that is delivered by a digital application (app) (the ExerciseRx app) works compared to health education in improving physical…
- Conditions
- Localized Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- EMPOWER (NCT07302230)
- Testing
- Internet-Based Intervention, Best Practice, Exercise Intervention
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Washington